Can Epriet shrink prostate hyperplasia?

Epristeride is a drug for the treatment of benign prostatic hyperplasia, which can reduce prostate gland and improve urinary tract obstruction symptoms. It is usually administered orally for 3 months. Adverse reactions include nausea, etc., and should be used with caution in patients with renal insufficiency. Children, the elderly and pregnant women should be used with caution. Epride can reduce benign prostatic hyperplasia. Epristeride is a drug for treating prostatic hyperplasia. Its main component is epride, which belongs to 4-azosteroid hormone compound. It can specifically inhibit type II 5 α-reductase, reduce the content of dihydrotestosterone (DHT) in serum and prostate, shrink prostate gland and improve urinary tract obstruction caused by prostatic hyperplasia. Epristeride is indicated for the treatment of benign prostatic hyperplasia (BPH). It can improve symptoms associated with BPH, such as frequent urination, urgency, thin urine line, dysuria, increased nocturnal urination, and incomplete urination. Epride is usually administered orally, 1 tablet (5 mg) twice a day, for 3 months. Or as prescribed. It should be noted that it is contraindicated for allergic patients; it should be used with caution for renal insufficiency; it should be used with caution for children, elderly patients and pregnant women. In addition, some adverse reactions may occur after taking Epristeride, such as nausea, loss of appetite, abdominal distension, diarrhea, dry mouth, dizziness, insomnia, general fatigue, rash, decreased libido, etc. If the adverse reactions are serious, seek medical advice promptly. In short, Epristeride can reduce prostate hyperplasia, but when using it, follow the doctor's advice and pay attention to adverse reactions. If there are symptoms related to prostate hyperplasia, it is recommended to seek medical attention promptly and treat under the guidance of a doctor.